Skip to main content
TipRanks
Go Ultimate75% OFF

HemoGenyx Pharmaceuticals Plc (5HU0) AI Stock Analysis

0 Followers
DE:5HU0

HemoGenyx Pharmaceuticals Plc

(Frankfurt:5HU0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Specialized hematology and stem-cell focusA focused pipeline in hematopoietic stem cells and hematology/oncology gives the company a defined scientific domain rather than a broad, undifferentiated research strategy. If its candidates demonstrate clinical value, this specialization could support differentiated intellectual property and partnership opportunities over time.
Negative Factors
No revenue generationA continuing absence of revenue leaves the business dependent on external funding while it advances its therapeutic programs. Without commercial sales, licensing income, or another established revenue stream, the company has limited internal capacity to finance research, absorb setbacks, or support operations.

HemoGenyx Pharmaceuticals Plc (5HU0) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%DE:5HU0+1.31%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 47.62M
Dividend Yield
―
Average Volume (3M)
89
Price to Earnings (P/E)
-3.8
Beta (1Y)
-0.45
Revenue Growth
―
EPS Growth
21.18%
Country
Germany
Employees
16
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model

Company Description

Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions...

HemoGenyx Pharmaceuticals Plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:5HU0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:APTAGB:APTA48NeutralGBP 10.40M-10.00-46.61%―28.35%50.00%
GB:POLBGB:POLB42NeutralGBP 48.10M-8.08-71.28%――31.58%
GB:HVOGB:HVO38UnderperformGBP 32.70M-2.64-35.13%4.21%-24.24%-329.49%
GB:IMMGB:IMM37UnderperformGBP 15.01M-1.92-559.87%――5.62%
GB:ARECGB:AREC33UnderperformGBP 34.43M152.003.75%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%DE:5HU0GB:IMMGB:HVOGB:POLBGB:ARECGB:APTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:5HU0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:5HU0Hemogenyx Pharmaceuticals Plc7.75-1.15-12.92%
GB:IMMImmuPharma plc2.40-7.36-75.36%
GB:HVOOpen Orphan Plc4.75-1.05-18.10%
GB:POLBPoolbeg Pharma Ltd.6.302.7075.00%
GB:ARECArecor Therapeutics PLC76.002.002.70%
GB:APTAAptamer Group Plc0.30-0.60-66.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.